Selpercatinib
Brand name: Retevmo
Selpercatinib comes in 9 pill versions in our database, in 4 strengths, from 2 manufacturers. Check the imprint to tell them apart.
Selpercatinib pill images
40 mg 3 pills
- Lilly 3977 40mg Selpercatinib 40 mg Gray, capsule, 18 mm Used for lung cancer and thyroid neoplasms
- Ret40 5340 Selpercatinib 40 mg Gray, round, 6 mm Used for lung cancer and thyroid neoplasms
- 5340 Ret 40 Selpercatinib 40 mg Gray, round Used for lung cancer and thyroid neoplasms
80 mg 4 pills
- Lilly 2980 80mg Selpercatinib 80 mg Blue, capsule, 22 mm Used for lung cancer and thyroid neoplasms
- Ret80 6082 Selpercatinib 80 mg Purple, round, 8 mm Used for lung cancer and thyroid neoplasms
- 6082 Ret 80 Selpercatinib 80 mg Purple & red, round Used for lung cancer and thyroid neoplasms
- 6082 Ret 80 Selpercatinib 80 mg Purple & red, round Used for lung cancer and thyroid neoplasms
120 mg 1 pill
160 mg 1 pill
What is Selpercatinib used for?
Selpercatinib is used for lung cancer and thyroid neoplasms.
- Medicine type
- Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label
RET Fusion-Positive Non-Small Cell Lung Cancer
RETEVMO® is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.
RET-Mutant Medullary Thyroid Cancer
RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.
RET Fusion-Positive Thyroid Cancer
RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
Other RET Fusion-Positive Solid Tumors
RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
From the FDA-approved label on DailyMed (published Sep 14, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.